IGC Pharma Company Description

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia.

The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s.

Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders.

The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.

IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

IGC Pharma, Inc.

Country	United States
Founded	2005
Industry	Pharmaceutical Preparations
Employees	70
CEO	Ram Mukunda

Contact Details

Address: 10224 Falls Road Potomac, Maryland 20854 United States
Phone	301 983 0998
Website	igcpharma.com

Stock Details

Ticker Symbol	IGS1
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	April - March
Reporting Currency	USD
SIC Code	2834

Key Executives

Name	Position
Ram Mukunda	Chief Executive Officer
Claudia Grimaldi	Chief Financial Officer
Benysh Qureshi	Chief Operating Officer